ORIC Pharmaceuticals, Inc. ORIC announced that it has collaborated with pharma giants Bayer BAYRY and Janssen Research & Development, LLC, a Johnson & Johnson JNJ company, to support its ongoing study ...
ORIC Pharmaceuticals (NASDAQ: ORIC) is a small-cap pharma stock. It aims to make a difference with its potentially “best-in-class” treatments. The company’s shares have not had a great year, returning ...
Financial Position: ORIC ended 2023 with $235.0 million in cash, cash equivalents, and investments, bolstered by $210 million from private placements. R&D Investments: R&D expenses increased to $85.2 ...
Oric Pharmaceuticals’ previously announced plan to focus resources on its two most advanced oncology drugs comes with a sting in its tail—the therapeutic-resistance-focused biotech is laying off 20% ...
Hosted on MSN
Ladenburg Thalmann Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Buy Recommendation
Fintel reports that on July 8, 2025, Ladenburg Thalmann initiated coverage of ORIC Pharmaceuticals (NasdaqGS:ORIC) with a Buy recommendation. Analyst Price Forecast Suggests 80.92% Upside As of June ...
Oric Pharmaceuticals specializes in oncology therapies. The company said the private placement will help it fund operations through the end of 2025. It has three therapies in phase 1 trials. Oric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback